Evidence map›Paper›PMID 25179404›Full record

ArticleJAMA internal medicine2014

Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas.

Trisha M Parekh, Mukaila Raji, Yu-Li Lin, Alai Tan, Yong-Fang Kuo, James S Goodwin

Open access · greenAbstract read
In one paragraph

Article in JAMA internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Glycemic Management in Adults With Diabetes During Illness.Clinical diabetes : a publication of the American Diabetes Association · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Trisha M ParekhSealy Center on Aging, University of Texas Medical Branch, Galveston2Department of Internal Medicine, University of Texas Medical Branch, Galveston3Department of Preventive Medicine, University of Texas Medical Branch, Galveston4Department of Community He.
Mukaila RajiSealy Center on Aging, University of Texas Medical Branch, Galveston2Department of Internal Medicine, University of Texas Medical Branch, Galveston3Department of Preventive Medicine, University of Texas Medical Branch, Galveston4Department of Community He.
Yu-Li LinSealy Center on Aging, University of Texas Medical Branch, Galveston2Department of Internal Medicine, University of Texas Medical Branch, Galveston3Department of Preventive Medicine, University of Texas Medical Branch, Galveston4Department of Community He.
Alai TanSealy Center on Aging, University of Texas Medical Branch, Galveston2Department of Internal Medicine, University of Texas Medical Branch, Galveston3Department of Preventive Medicine, University of Texas Medical Branch, Galveston4Department of Community He.
Yong-Fang KuoSealy Center on Aging, University of Texas Medical Branch, Galveston2Department of Internal Medicine, University of Texas Medical Branch, Galveston3Department of Preventive Medicine, University of Texas Medical Branch, Galveston4Department of Community He.
James S GoodwinSealy Center on Aging, University of Texas Medical Branch, Galveston2Department of Internal Medicine, University of Texas Medical Branch, Galveston3Department of Preventive Medicine, University of Texas Medical Branch, Galveston4Department of Community He.
The University of Texas Medical Branch at Galveston · US

Funding

UTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7M
UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
Patient Centered Outcomes Research in the ElderlyR24HS022134 · AHRQ · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GOODWIN, MD, JAMES S. · 2013 to 2017
$4.8M
Care of the elder hospitalized patient: the role of the hospitalistsR01AG033134 · NIA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GOODWIN, MD, JAMES S. · 2009 to 2018
$2.2M
Established Investigator Award in Cancer Prevention & ControlK05CA134923 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GOODWIN, MD, JAMES S. · 2008 to 2019
$1.0M
AHRQ HHS 1R24HS022134-0AHRQ HHS R24 HS022134NCATS NIH HHS UL1 TR000071NCATS NIH HHS UL1TR000071NCI NIH HHS K05 CA134923NIA NIH HHS P30 AG024832NIA NIH HHS R01 AG033134
6 · The paper itself

Abstract

importanceCertain antimicrobial drugs interact with sulfonylureas to increase the risk of hypoglycemia.

objectiveTo determine the risk of hypoglycemia and associated costs in older patients prescribed glipizide or glyburide who fill a prescription for an antimicrobial drug. DESIGN, SETTING, AND

participantsThis was a retrospective cohort study of Texas Medicare claims from 2006 to 2009 for patients 66 years or older who were prescribed glipizide or glyburide and who also filled a prescription for 1 of the 16 antimicrobials most commonly prescribed for this population.

methodsWe assessed hypoglycemia events and associated Medicare costs in patients prescribed 1 of 7 antimicrobial agents thought to interact with sulfonylureas, using noninteracting antimicrobials as a comparison. We used a repeated measure logistic regression, controlling for age, sex, ethnicity, Medicaid eligibility, comorbidity, prior emergency department visits for hypoglycemia, prior hospitalizations for any cause, nursing home residence, and indication for the antimicrobial. We estimated odds of hypoglycemia, number needed to harm, deaths during hospitalization for hypoglycemia, and Medicare costs for hypoglycemia treatment. MAIN OUTCOMES AND MEASURES: Any hospitalization or emergency department visit owing to hypoglycemia within 14 days of antimicrobial exposure.

resultsIn multivariable analyses controlling for patient characteristics and indication for antimicrobial drug use, clarithromycin (odds ratio [OR], 3.96 [95% CI, 2.42-6.49]), levofloxacin (OR, 2.60 [95% CI, 2.18-3.10]), sulfamethoxazole-trimethoprim (OR, 2.56 [95% CI, 2.12-3.10]), metronidazole (OR, 2.11 [95% CI, 1.28-3.47]), and ciprofloxacin (OR, 1.62 [95% CI, 1.33-1.97]) were associated with higher rates of hypoglycemia compared with a panel of noninteracting antimicrobials. The number needed to harm ranged from 71 for clarithromycin to 334 for ciprofloxacin. Patient factors associated with hypoglycemia included older age, female sex, black or Hispanic race/ethnicity, higher comorbidity, and prior hypoglycemic episode. In 2009, 28.3% of patients prescribed a sulfonylurea filled a prescription for 1 of these 5 antimicrobials, which were associated with 13.2% of all hypoglycemia events in patients taking sulfonylureas. The treatment of subsequent hypoglycemia adds $30.54 in additional Medicare costs to each prescription of 1 of those 5 antimicrobials given to patients taking sulfonylureas. CONCLUSIONS AND RELEVANCE: Prescription of interacting antimicrobial drugs to patients on sulfonylureas is very common, and is associated with substantial morbidity and increased costs.

Indexed as

AgedAged, 80 and overAnti-Infective AgentsCiprofloxacinClarithromycinDrug InteractionsDrug PrescriptionsFemaleGlipizideGlyburideHealth Care CostsHumansHypoglycemiaHypoglycemic AgentsLevofloxacinLogistic ModelsAnti-Infective AgentsCiprofloxacinClarithromycinGlipizideGlyburideHypoglycemic AgentsLevofloxacinMetronidazoleSulfonylurea CompoundsTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID25179404
PMCPMC4878670
OpenAlexW2110349466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.